Alzheimer’s Steadfast Study

What we are studying

The purpose of this research study is to determine whether an investigational drug, azeliragon (TTP488) is safe and beneficial in delaying or altering the decline in memory and daily functioning when given to people with mild Alzheimer’s disease (AD). In this 23 month study, participants will be given either active study drug, azeliragon or placebo. A study partner is needed to participate.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 50+

Eligibility Criteria

  • Participants must have a caregiver/informant
  • Ability to read and write
  • Non-Childbearing potential
  • Diagnosis of probable AD
  • Must be on stable dose of cholinesterase inhibitor and/or memantine for at least 3 months prior to randomization.

What is involved

  • There will be at least 9 in-person visits
  • Memory tests
  • 3 MRI scans (1 CT scan if pt is unable to have MRI)
  • 3 FDG PET scans
  • 2 telephone checks
  • 9 blood draws.


Enrolled participants will receive $50 per completed visit to compensate them for transportation.

Contact Information

Study Coordinator
Tim Collare
[email protected]

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.